ADVFN - Advanced Financial Network.
HOME» NASDAQ » A » ACOR Stock Price » ACOR Stock News

Acorda Therapeutics Share News

 Acorda Therapeutics (mm) Stock Price
ACOR Stock Price
 Acorda Therapeutics (mm) Stock Chart
ACOR Stock Chart
 Acorda Therapeutics (mm) Stock News
ACOR Stock News
 Acorda Therapeutics (mm) Company Information
ACOR Company Information
 Acorda Therapeutics (mm) Stock Trades
ACOR Stock Trades

Acorda To Pay Up To $35 Million To Medtronic In Licensing Deal

DOW JONES NEWSWIRES Acorda Therapeutics Inc. (ACOR) will pay up to $35 million to Medtronic Inc. (MDT) for global development and commercialization rights to the medical-device maker's magnesium formulation as a potential treatment for neurological traumas like spinal cord and brain injuries. Medtronic gets a $3 million upfront payment and up to $32 million in milestone payments, plus potential single-digit sales royalties if Acorda commercializes the clinical-stage compound. Medtronic has some nonexclusive rights with Acorda in certain areas such as pain and musculoskeletal indications. Acorda President and Chief Executive Ron Cohen said the magnesium formulation is an important addition to the company's pipeline of drug candidates. The treatment received Food and Drug Administration fast-track designation in February 2009 for spinal cord injury patients. Acorda plans to seek orphan drug designation in the U.S. Fast-track status typically is given to treatments for life-threatening conditions for which no other drug exists or works as well. Orphan drug status is to encourage development of drugs for rare diseases. Medtronic in May reported its fiscal fourth-quarter earnings fell 19%, hit by restructuring costs linked to recent job cuts, while sales edged higher despite a drag from continued growth challenges in markets for implantable defibrillators and spinal devices. Acorda in May reported that its first-quarter performance fell short of estimates amid disappointing sales of its Ampyra drug, which is used to improve walking ability of multiple sclerosis patients. Shares of Acorda and Medtronic closed Thursday at $32.31 and $38.53, respectively. Neither was active premarket. -By Tess Stynes, Dow Jones Newswires; 212-416-2481; Tess.Stynes@dowjones.com

Stock News for Acorda Therapeutics (ACOR)
DateTimeHeadline
04/23/201507:00:00Acorda Therapeutics to Host Conference Call to Discuss First...
04/22/201507:56:12Current Report Filing (8-k)
04/22/201507:30:00Acorda Presents Data on First Clinical Study of Remyelinating...
04/22/201507:01:00Acorda Therapeutics Named One of the Best Places to Work For...
04/22/201504:49:35Acorda Therapeutics Research Coverage Started at Piper Jaffray...
04/19/201514:07:03This New Hedge Fund Strategy Just Might Be Crazy Enough To Work
04/19/201513:01:02Will This Hedge Fund Manager Bring Down Your Biotech Stocks?
04/08/201512:55:14Confidential Treatment Order (ct Order)
04/07/201519:51:27Kyle Bass's New Tack: Dispute the Patent, Short the Stock
04/07/201516:49:59Hedge-Fund Manager Challenges Jazz Pharmaceuticals Patent
03/18/201506:02:49Not In Favor Of The Solar Industry - Cramer's Lightning Round...
03/16/201512:13:00Acorda Rings NASDAQ Opening Bell to Mark 20th Anniversary
03/13/201510:00:00Acorda Therapeutics, Inc. (ACOR) to Ring The Nasdaq Stock Market...
03/10/201507:00:00Acorda to Present New Analyses of Cimaglermin alfa (GGF2) Data...
03/06/201518:33:47Statement of Changes in Beneficial Ownership (4)
03/06/201518:32:50Statement of Changes in Beneficial Ownership (4)
03/06/201518:31:54Statement of Changes in Beneficial Ownership (4)
03/06/201518:30:24Statement of Changes in Beneficial Ownership (4)
03/06/201518:28:17Statement of Changes in Beneficial Ownership (4)
03/06/201518:27:27Statement of Changes in Beneficial Ownership (4)

Acorda Therapeutics and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad